Botulinum toxin A topical - Revance Therapeutics

Drug Profile

Botulinum toxin A topical - Revance Therapeutics

Alternative Names: BoNTA; DaxibotulinumtoxinA Topical gel; RT 001 - Revance; RT-001

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revance Therapeutics
  • Class Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Migraine
  • Preclinical Neuropathic pain
  • Discontinued Facial-wrinkles; Hyperhidrosis

Most Recent Events

  • 04 Aug 2016 Revance Therapeutics has patent protection for botulinum toxin-related applications
  • 01 Aug 2016 Revance Therapeutics completes the phase III REALISE 1 trial in Facial wrinkles in USA (NCT02580370)
  • 13 Jun 2016 Discontinued - Phase-II for Hyperhidrosis in USA as the phase III Realise 1 trial failed to achieve its primary endpoint (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top